Prostaglandin System and Inflammation

  • G. P. Velo
  • M. E. Fracasso
  • R. Leone
  • R. Milanino
Part of the NATO Advanced Study Institutes Series book series


Prostaglandins (PGs) were first described by Goldblatt and von Euler, in the early thirties, as compounds contained in the crude extract of seminal vesicles and capable of lowering blood pressure and contracting smooth muscles, especially those coming from the gastro-intestinal tract (1,2).


Arachidonic Acid Vascular Permeability Polymorphonuclear Leukocyte Arachidonic Acid Cascade Prostaglandin Endoperoxide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    M. W. Goldblatt, A depressor substance in seminal fluid, J. Soc. Chem. Ind., 52: 1056 (1933).Google Scholar
  2. 2.
    U. S. von Euler, On the specific vasodilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin), J. Physiol88:213 (1936).Google Scholar
  3. 3.
    B. Samuelsson, P. Borgeat, S. Hammarström and R. C. Murphy, Introduction of a nomenclature: Leukotrienes,Abstract, Paper presented during the Prostaglandin Conference in Washington 28–31 May, 1979.Google Scholar
  4. 4.
    M. Hamberg and B. Samuelsson, Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets, Proc. Natl. Acad. Sci. USA 71: 3400 (1974).PubMedCrossRefGoogle Scholar
  5. 5.
    D. A. Nugteren, Arachidonate lipoxygenase in blood platelets, Biochim. BiophysActa., 380:299 (1975).PubMedCrossRefGoogle Scholar
  6. 6.
    S. Hammarström, M. Ramberg, B. Samuelsson, E. A. Duell, M. Stawiski and J. J. Voorhees, Increased concentrations of free arachidonic acid, prostaglandins E2 and F2 and of 12Lhydroxy-5,8,10,14 - eicosatetraenoic acid (HETE) in epidermis of psoriasis; Evidence for perturbed regulation of arachidonic acid levels in psoriasis, Proc. Natl. Acad. Sci. USA 72: 5130 (1975).PubMedCrossRefGoogle Scholar
  7. 7.
    S. R. Turner, J. A. Tainer and W. S. Lynn, Biogenesis of chemotactic molecules by the arachidonate lipoxygenase system of platelets, Nature, 257: 680 (1975).PubMedCrossRefGoogle Scholar
  8. 8.
    E. J. Goetzl, J. M. Woods and R. R. Gorman, Stimulation of human eosinophil and neutrophil polymorphonuclear leukocyte chemotaxis and random migration by 12-L-hydroxy-5,8,10,14eicosatetraenoic acid, J. Clin. Invest59:179 (1977).PubMedCrossRefGoogle Scholar
  9. 9.
    E. Horton, Action of prostaglandin El on tissues which respond to bradykinin, Nature 200: 892 (1963).Google Scholar
  10. 10.
    L. M. Solomon, L. Juhlin and M. B. Kirschenbaum, Prostaglandin on cutaneous vasculature, J. Invest. Derm51:280 (1968).PubMedGoogle Scholar
  11. 11.
    P. Crunkhorn and A. L. Willis, Actions and interactions of prostaglandin administered intradermally in rat and in man, Br. J. Pharmac., 36: 216P (1969).Google Scholar
  12. 12.
    P. Crunkhorn and A. L. Willis, Cutaneous reactions to intra-dermal prostaglandins, Br. J. Pharmac41:49 (1971).CrossRefGoogle Scholar
  13. 13.
    J. S. S$ndergaard and M. W. Greaves, Continuous skin perfusion in vitro as a method for study of pharmacological agents in human skin, Acta Dermatovener51: 50 (1971).Google Scholar
  14. 14.
    S. Moncada, S. H. Ferreira and J. R. Vane, Prostaglandins, aspirin-like drugs and the oedema of inflammation, Nature 246: 217 (1973).Google Scholar
  15. 15.
    G. Thomas and G. B. West, Prostaglandins, kinin and inflammation in the rat, Br. J. Pharmac50:231 (1974).CrossRefGoogle Scholar
  16. 16.
    G. Kaley and R. Weiner, Effect of prostaglandin E on leucocyte migration, Nature New Biology 234: 114 (1971).Google Scholar
  17. 17.
    J. S. SØSndergaard and P. Wolf-Jorgensen, The cellular exudate of human cutaneous inflammation induced by prostaglandins E1 and Fla, Acta. Dermatovener 52:361 (1972).Google Scholar
  18. 18.
    S. H. Ferreira, Prostaglandins, aspirin-like drugs and analgesia, Nature New Biology 240: 200 (1972).Google Scholar
  19. 19.
    M. W. Greaves and W. McDonald-Gibson, Itch: role of prostaglandins, Br. MedJ., 3:608 (1973).CrossRefGoogle Scholar
  20. 20.
    A. S. Milton and S. Wendlandt, A possible role for prostaglandin El as a modulator for temperature regulation in the central nervous system in the cat, J. Physiol. (Loud.) 207:76P (1970).Google Scholar
  21. 21.
    W. Feldberg and P. N. Saxena, Fever produced by prostaglandin El, J. Physiol. (tond.) 317:547 (1971).Google Scholar
  22. 22.
    J. B. Smith, M. J. Silver, C. M. Ingerman and J. J. Kocsis, Prostaglandin D2 inhibits the aggregation of human platelets, Thrombosis Res5: 291 (1974).CrossRefGoogle Scholar
  23. 23.
    E. E. Nishizawa, W. L. Miller, R. R. Gorman, G. L. Bundy, J. Svensson and M. Hamberg, Prostaglandin D2 as a potential antithrombotic agent, Prostaglandins 9: 109 (1975).Google Scholar
  24. 24.
    R. J. Flower, E. A. Harvey and W. P. Kingston, Inflammatory effects of prostaglandin D2 in rat and human skin, Br. J. Pharmac56:229 (1976).CrossRefGoogle Scholar
  25. 25.
    J. R. Vane, Prostaglandins as mediators of inflammation, in: Advances in Prostaglandin. and’Thromboxane Research, Vol.2, B. Samuelsson and R. Paoletti, , p. 791 ( Raven Press, New York, 1976 ).Google Scholar
  26. 26.
    0. Hagermark, K. Strandberg and M. Hamberg, Potentiating effects of prostaglandin E2 and the prostaglandin endoperoxide PGH2 on cutaneous responses in man J. Invest Derm., 66:266P (1976).Google Scholar
  27. 27.
    G. P. Lewis, J. Westwick and T. J. Williams, Microvascular responses produced by the prostaglandin endoperoxide PGG2 in vivo, Br’. J. Pharmac 59:442P (1977).Google Scholar
  28. 28.
    G. A. Higgs, S. Moncada and J. R. Vane, Prostacyclin as a potent dilator of arterioles in the hamster cheek pouch, J. Physiol. (Lond.) 275:30P (1978).Google Scholar
  29. 29.
    S. Samuelsson, Introduction: new trends in prostaglandin research, in: Advances in Prostaglandin and Thromboxane Research, Vol. 1, B. Samuelsson and R. Paoletti, , p. 1 ( Raven Press, New York, 1976 ).Google Scholar
  30. 30.
    J. R. Boot, W. Dawson and E. A. Kitchen, The chemotactic activity of thromboxane B2: A possible role in inflammation, J. Physiol257:47P (1976).Google Scholar
  31. 31.
    S-I. Murota, W-C. Chang, S. Tsurufuji and I. Morita, The possible roles of prostacyclin (PGI2) and thromboxanes in chronic inflammation, in: Advances in Inflammation Research, Vol. 1, G. Weissmann,B. Samuelsson, R. Paoletti, , P.439 (Raven Press, New York,1979).Google Scholar
  32. 32.
    S. Bunting, R. Gryglewski, S. Moncada and J. R. Vane, Arterial walls generate from prostaglandin endoperoxides a substance (Prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelets aggregation, Prostaglandins 12: 897 (1976).Google Scholar
  33. 33.
    G. J. Dusting, S. Moncada and J. R. Vane, Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachidonic acid, Prostaglandins 13: 3 (1977).Google Scholar
  34. 34.
    S. Moncada, R. J. Gryglewski, S. Bunting and J. R. Vane, Further studies on the enzymatic conversion of prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation, Nature 263: 663 (1976).Google Scholar
  35. 35.
    S-I. Murota, I. Morita, S. Tsurufuji, H. Sato and K. Sugio, Effect of prostaglandin I2 and related compounds on vascular permeability response in granuloma tissues, Prostaglandins 15: 297 (1978).Google Scholar
  36. 36.
    M. J. Peck and T. J. Williams, Prostacyclin (PGI2) potentiates bradykinin-induced plasma exudation in rabbit skin, Br. J. Pharmac62:464P (1978).Google Scholar
  37. 37.
    E. A. Higgs, S. Moncada and J. R. Vane, Inflammatory effects of prostacyclin (PGI2) and 6-oxo-PGFla in the rat paw, Prostaglandins 16: 153 (1978).Google Scholar
  38. 38.
    A. W. Ford-Hutchinson, J. R. Walker, E. M. Davidson and M. J. H. Smith, PGI2: a potential mediator of inflammation, Prostaglandins 16: 253 (1978).Google Scholar
  39. 39.
    K. Komoriya,H. Ohmori, A. Azuha, S. Kurozumi, Y. Hashimoto, K. Nicolaou, W. E. Barnette and R. L. Magolda, Prostaglandin 12 as a potentiator of acute inflammation in rats, Prostaglandins 15: 557 (1978).Google Scholar
  40. 40.
    G. A. Higgs, E. A. Higgs and J. A. Salmon, Prostacyclin in inflammation, in: Prostacyclin, J. R. Vane and S. Bergström , p. 187 (Raven Press, New York,1979).Google Scholar
  41. 41.
    S. H. Ferreira, M. Nakamura and M. S. Abreu Castro, The hyperalgesic effects of prostacyclin and PGE2, Prostaglandins 16: 31 (1978).Google Scholar
  42. 42.
    K.Hillier and S. M. M. Karim, Effects of prostaglandins El, E2, Fla and Fla on isolated human umbilical and placental blood vessels, J. Obstet. Gynaec. Br. Commonwealth 75:667 (1968).Google Scholar
  43. 43.
    P. Crunkhorn and A. L. Willis, Interaction between prostaglandins E and F given intradermally in the rat, Br. JPharmac., 41:507 (1971).Google Scholar
  44. 44.
    G. P. Velo, C. J. Dunn, J. P. Giroud, J. Timsit and D. A. Willoughby, Distribution of prostaglandins in inflammatory exudate, J. Pathol111:149 (1973).Google Scholar
  45. 45.
    D. A. Willoughby, J. P. Giroud, G. P. Velo, Progrès dans l’ inflammation applicable à la polyarthrite cronique évolutive, Brux. Med54:135 (1974).PubMedGoogle Scholar
  46. 46.
    N. D. Goldberg, M. K. Haddox, D. K. Hartle and J. W. Hadden, The biological role of cyclic 3’-5’-guanosine monophosphate, in: Pharmacology and the Future of Man, Vol. 5, G. H. Acheson Ed., p.146 (Karger, Base1,1973).Google Scholar
  47. 47.
    G. P. Velo and S. E. Abdullahi, General concepts of inflammation, in: Inflammatory Arthropathies, E. C. Huskisson and G. P. Velo,, p. 3 ( Excerpta Medica, Amsterdam, 1976 ).Google Scholar
  48. 48.
    J. P. Giroud, G. P. Velo and D. A. Willoughby, The role of prostaglandins and cyclic nucleotides in inflammation, in: Prostaglandins and Thromboxanes, F. Berti, B. Samuelsson and G. P. Velo, , p. 323 ( Plenum Press, New York, 1977 ).CrossRefGoogle Scholar
  49. 49.
    B. B. Weksler, J. M. Knapp and E. A. Jaffe, Prostacyclin (PGI2) synthesized by cultured endothelial cells modulates polymorphonuclear leukocyte function, Blood 50(5) suppl.l: 287 (1977).Google Scholar
  50. 50.
    G. A. Higgs, S. Moncada and J. R. Vane, Prostacyclin reduces the number of “slow moving” leukocytes in hamster cheek pouch venules, J. Physiol280:55P (1978).Google Scholar
  51. 51.
    J. E. Tateson, S. Moncada and J. R. Vane, Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets, Prostaglandins 13: 389 (1977).Google Scholar
  52. 52.
    J. Rivikin, J. Rosenblatt and E. L. Becker, The role of cyclic AMP in the chemotactic responsiveness and spontaneous motility of rabbit peritoneal neutrophils, J. Immunol115:1126 (1974).Google Scholar
  53. 53.
    N. Ambache, L. Kavanagh and J. Whiting, Effect of mechanical stimulation on rabbit eyes: release of active substances in anterior chamber perfusates, J. Physiol(Lond.), 176: 378 (1965).PubMedGoogle Scholar
  54. 54.
    A. L. Willis, Parallel assay of prostaglandin-like activity in rat inflammatory exudate by means of cascade superfusion J. Pharm. Pharmac 21:126 (1969). Google Scholar
  55. 55.
    A. J. Anderson, W. E. Brocklehurst and A. L. Willis, Evidence for the role of lysosomes in the formation of prostaglandins during carrageenin-induced inflammation in the rat Pharmac. Res. Comm 3:13 (1971). CrossRefGoogle Scholar
  56. 56.
    D. R. Robinson and L. Levine, Prostaglandin concentrations in synovial fluids in rheumatic diseases, in: 66th Annual Meeting of the American Society for Clinical Investigation, Abstr., 246 (1974).Google Scholar
  57. 57.
    D. R. Robinson, M. B. MacGuire and L. Levine, Prostaglandins in the rheumatic diseases, Ann. N.Y. Acad. Sci256:318 (1975).Google Scholar
  58. 58.
    G. A. Higgs and J. A. Salmon, Cyclo-oxygenase products in carrageenin-induced inflammation, Prostaglandins 17: 737 (1979).Google Scholar
  59. 59.
    J. A. Splawinski, B. Wojtaszek, J. Swies and R. J. Gryglewski, Endogenous factors affecting arachidonic acid metabolism: I. Biosynthesis of prostacyclin and prostaglandins by carrageenin granulomas of rats, Prostaglandins 16: 683 (1978).Google Scholar
  60. 60.
    B. A. Peskar and K. Brune, Prostaglandin D2: The prevailing prostaglandin in acute inflammation, in: Arachidonic Acid Metabolism in Inflammation and Thrombosis, K. Brune and M. Baggiolini, , p.260 (Birkhäuser, Base1,1979).Google Scholar
  61. 61.
    L. E. Trang, E. Granstrom and 0. Lovgren, Levels of prostaglandins F2a and E2 and thromboxane B2 in joint fluid in rheumatoid arthritis, Scand. J. Rheum6:151 (1977).PubMedCrossRefGoogle Scholar
  62. 62.
    W-C. Chang, S-I. Murota, M. Matsuo and S. Tsurufuji, A new prostaglandin transformed from arachidonic acid in carrageenin-induced granuloma, Biochem. Res. Commun72:1259 (1976)Google Scholar
  63. 63.
    W-C. Chang, S-I. Murota and S. Tsurufuji, Thromboxane B2 transformed from arachidonic acid in carrageenin-induced granuloma, Prostaglandins, 13: 17 (1977).PubMedGoogle Scholar
  64. 64.
    J. Sindergaard and M. W. Greaves, Release of prostaglandins in human cutaneous sustained inflammatory reactions, in: Future Trends in Inflammation, G. P. Velo, D. A. Willoughby, J. P. Giroud, , p. 45 ( Piccin, Padova 1974 ).Google Scholar
  65. 65.
    M. W. Greaves and J. S. Sgndergaard, Pharmacological agents released in ultraviolet inflammation studied by cutaneous skin perfusion, J. Invest. Derm54:365 (1970).Google Scholar
  66. 66.
    R. B. Zurier and D. M. Sayadoff, Release of prostaglandins from human polymorphonuclear leukocytes, Inflammation 1: 93 (1975).Google Scholar
  67. 67.
    G. A. Higgs, M. E. McCall and L. J. F. Youlten, A chemotactic role for prostaglandins released from polymorphonuclear leukocytes during phagocytosis, Br. J. Pharmac53:539 (1975).Google Scholar
  68. 68.
    G. A. Higgs, S. Bunting, S. Moncada and J. R. Vane, Polymorphonuclear leukocytes produce thromboxane A2-like activity during phagocytosis, Prostaglandins 12: 749 (1976).Google Scholar
  69. 69.
    I. M. Goldstein, C. L. Malmsten, H. B. Kaplan, H. Jindahl, B. Samuelsson and G. Weissmann, Thromboxane generation by stimulated human granulocytes. Inhibition by glucocorticoids and superoxide dismutase, Clin. Res25:518A (1977).Google Scholar
  70. 70.
    E. M. Davison, A. W. Ford-Hutchinson, M. J. H. Smith and J. R. Walker, The release of thromboxane B2 by rabbit peritoneal polymorphonuclear leukocytes, Br. J. Pharmac63:407P (1978).Google Scholar
  71. 71.
    D. Gordon, M. A. Bray and J. Morley, Control of lymphokine secretion by prostaglandins, Nature 262: 401 (1976).Google Scholar
  72. 72.
    J. L. Humes, R. J. Bonney, L. Pelus, M. E. Dahlgran, S. J. Sadowski, F. A. Kuehl Jr. and P. Davies, Macrophages synthesise and release prostaglandins in response to inflammatory stimuli, Nature 269: 149 (1977).Google Scholar
  73. 73.
    M. Glatt, H. Kä.lin, K. Wagner and K. Brune, Prostaglandins release from macrophages: An assay system for anti-inflammatory drugs in vitro Agents and Actions, 7: 321 (1977).Google Scholar
  74. 74.
    J. Morley, M. A. Bray R. W. Jones, D. H. Nugteren and D. A. van Dorp, Prostaglandin and thromboxane production by human and guinea-pig macrophages and leucocytes, Prostaglandins 17: 730 (1979).Google Scholar
  75. 75.
    J. R. Boot, W. Dawson and E. A. Kitchen, The chemotactic activity of thromboxane B2: A possible role in inflammation, JPhysiol, 257:47P (1976)Google Scholar

Copyright information

© Plenum Press, New York 1981

Authors and Affiliations

  • G. P. Velo
    • 1
  • M. E. Fracasso
    • 1
  • R. Leone
    • 1
  • R. Milanino
    • 2
  1. 1.Istituto di FarmacologiaUniversità di Padova, Policlinico Borgo RomaVeronaItalia
  2. 2.Dipartimento di Farmacologia, Divisione RicercheLaboratori Glaxo S.p.a.—Duncan Farmaceutici S.p.aVeronaItalia

Personalised recommendations